A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis
Phase 2
Completed
- Conditions
- inflamatory bowel diseaseUlcerative colitis10017969
- Registration Number
- NL-OMON46940
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
Trial is onging in other countries
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 7
Inclusion Criteria
This study will include male or female subjects >=18 and <=75 years of age with moderate to severe active UC (defined as a Mayo score of 6 to 12 with an endoscopic subscore >=2).
Exclusion Criteria
This study will include male or female subjects >=18 and <=75 years of age with moderate to severe active UC (defined as a Mayo score of 6 to 12 with an endoscopic subscore >=2).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary efficacy endpoint is the clinical remission at Week 12</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary efficacy endpoints are clinical response at Week 12 and endoscopic<br /><br>remission at Week 12 and Week 52</p><br>